Characteristics of complex therapy of immuno-inflammatory rheumatic diseases in COVID-19 pandemic conditions
DOI: 10.32364/2587-6821-2021-5-5-260-267
R.R. Samigullina, V.I. Mazurov, E.A. Trofimov
North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg,
Russian Federation
The rapid spread of a new coronavirus infection (COVID-19) requires innovative solutions, including tactics optimization in using genetically engineered and targeted drugs in patients with immuno-inflammatory rheumatic diseases (RD). The authors studied the characteristics of the complex therapy of immuno-inflammatory RD in the COVID-19 pandemic conditions, analyzed the COVID-19 course in patients with RD who received combined therapy with genetically engineered and basic synthetic anti-rheumatic drugs and were under follow-up from March 2020 to March 2021. The researchers found that synthetic basic (methotrexate, leflunomide, etc.), targeted synthetic (tofacitinib, baricitinib, apremilast) and biologic disease-modifying antirheumatic drugs used in the RD treatment, except high-dose glucocorticoids and anti-B cell drugs (rituximab), do not have a negative effect and are not associated with a severe COVID-19 course. The use of interleukin-6 (IL-6) inhibitors is the standard pathogenetic therapy for cytokine release syndrome in COVID-19. Proactive therapy with IL-6 inhibitors provides inhibition of systemic inflammation and contributes to the suppression of cytokine storm syndrome, preventing the development of multiple organ failure and fatal outcome.
Keywords: rheumatic diseases, cytokine storm, multiple organ failure, genetically engineered biological drugs, interleukin-6, COVID-19.
For citation: Samigullina R.R., Mazurov V.I., Trofimov E.A. Characteristics of complex therapy of immuno-inflammatory rheumatic diseases in COVID-19 pandemic conditions. Russian Medical Inquiry. 2021;5(5):260–267 (in Russ.). DOI: 10.32364/2587-6821-2021-5-5-260-267.
Aknowledgement
The technical edition is supported by BIOCAD JSC.
About the authors:
Ruzana R. Samigullina — Assistant Professor of the Department of Therapy, Rheumatology, Temporary Disability Examination and Quality of Medical Care named after E.E. Eichwald, North-Western State Medical University named after I.I. Mechnikov; 41, Kirochnaya str., Saint Petersburg, 191015, Russian Federation; ORCID iD 0000-0002-6341-3334.
Vadim I. Mazurov — Academician of the Russian Academy of Sciences, Honored Scientist of the Russian Federation, Dr. Sc. (Med.), Professor, Chief Scientific Consultant, Director of the Research Institute of Rheumatology, Head of the Department of Therapy, Rheumatology, Temporary Disability Examination and Quality of Medical Care named after E.E. Eichwald, North-Western State Medical University named after
I.I. Mechnikov; 41, Kirochnaya str., Saint Petersburg, 191015, Russian Federation; ORCID iD 0000-0002-0797-2051.
Evgeny A. Trofimov — C. Sc. (Med.), Associate Professor of the Department of Therapy, Rheumatology, Temporary Disability Examination and Quality of Medical Care named after E.E. Eichwald, North-Western State Medical University named after I.I. Mechnikov; 41, Kirochnaya str., Saint Petersburg, 191015, Russian Federation; ORCID iD 0000-0003-3236-4485.
Contact information: Ruzana R. Samigullina, e-mail: dr.samigullina@yandex.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 14.07.2021.
Revised 06.08.2021.
Accepted 31.08.2021.
2. Saiganov S.A., Mazurov V.I., Melnikov E.S., Lataria E.L. Possibilities of using Janus kinase inhibitors in the complex treatment of patients with COVID-19. Vestnik Severo-Zapadnogo gosudarstvennogo meditsinskogo universiteta im. I.I. Mechnikova. 2020;12(4):15–24 (in Russ.). DOI: 0.17816/mechnikov45894.
3. Nasonov E.L., Leela A.M., Mazurov V.I. et al. Coronavirus Disease 2019 (COVID-19) and Immunoinflammatory Rheumatic Diseases. Recommendations of the All-Russian public organization "Association of Rheumatologists of Russia". Nauchno-prakticheskaya revmatologiya. 2021;59(3):239–254 (in Russ.). DOI: 10.47360/1995-4484-2021-239-254.
4. Zhang Y., Li J., Zhan Y. et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun. 2004;72(8):4410–4415. DOI: 10.1128/IAI.72.8.4410-4415.2004.
5. Lau S.K.P., Lau C.C.Y., Chan K.H. et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol. 2013;94(Pt 12):2679–2690. DOI: 10.1099/vir.0.055533-0.
6. Chen X., Zhao B., Qu Y. et al. Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019. Clin Infect Dis. 2020;71(8):1937–1942. DOI: 10.1093/cid/ciaa449.
7. Herold T., Jurinovic V., Arnreich C. et al. Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. (Electronic resource.) URL: https://www.medrxiv.org/content/10.1101/2020.04.01.20047381v2.article-info (access date: 08.07.2021).
8. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5.
9. Karakike E., Giamarellos-Bourboulis E.J. Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis. Front Immunol. 2019;10:55. DOI: 10.3389/fimmu.2019.00055.
10. Clinical studies of the drug Ilsira® (Levilimab). (Electronic resource.) URL: https://ilsira.ru/clinical_researches (access date: 08.07.2021) (in Russ.).
11. Interim guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 11» (approved by the Ministry of Health of the Russian Federation on May 7, 2021). (Electronic resource.) URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/055/735/original/BMP_COVID-19.pdf (access date: 08.07.2021) (in Russ.).
This work is licensed under a Creative Commons «Attribution» 4.0 License.
